Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tafamidis Free Acid Tablet vs Capsule
NCT06705569Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM) (2 arms), sponsored by Pfizer. Primary endpoints: Area under the concentration-time curve from time zero to infinity at 168 hours and Maximum observed plasma concentration at 168 hours. Started Dec 2024; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT06705569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705569.